Literature DB >> 402577

Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension.

W B Stason, M C Weinstein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402577     DOI: 10.1056/NEJM197703312961307

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  42 in total

Review 1.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Current studies in pharmacoeconomics.

Authors:  J J Caro
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

3.  First principles of cost-effectiveness analysis in health.

Authors:  D S Shepard; M S Thompson
Journal:  Public Health Rep       Date:  1979 Nov-Dec       Impact factor: 2.792

4.  Should public health respect autonomy?

Authors:  S A Hall
Journal:  J Med Ethics       Date:  1992-12       Impact factor: 2.903

5.  Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

Authors:  B R Luce
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 6.  The economics of shared care packages.

Authors:  S M McGhee; A J Hedley
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

7.  Cost-effectiveness of ursodiol: the creature from the black box.

Authors:  A K Diehl
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

Review 8.  Clinical trials and clinical practice in the elderly. A focus on hypertension.

Authors:  M E Kitler
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

9.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.